Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.

Ulf Karlsson Johanna Repits Liselotte Antonsson Erik Cederfjäll Bengt Ljungberg Martin Ålenius Alan Sabirsh Magnus Gisslen Joakim Esbjörnsson Marianne Jansson

J Acquir Immune Defic Syndr

Departments of *Clinical Sciences †Laboratory Medicine ‡Experimental Medical Science, Lund University, Lund, Sweden §Department of Neuroscience, CNS and Pain, AstraZeneca R&D, Södertälje, Sweden ‖Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden ¶Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom **Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Published: March 2016

Supplemental Digital Content is Available in the Text.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770368	PMC
http://dx.doi.org/10.1097/QAI.0000000000000873	DOI Listing

Publication Analysis

Top Keywords

reduced baseline

baseline sensitivity

sensitivity maraviroc

maraviroc inhibition

inhibition hiv-1

hiv-1 isolates

isolates individuals

individuals severe

severe immunodeficiency

immunodeficiency supplemental

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!